GlassScriptPhysician profile
Vernon A Osborn
NPI 1023491677
$12,276.38
in general payments reported to CMS, 2019-2025
22 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $984 · 2022: $558 · 2023: $777 · 2024: $9,610 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,950 · Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,950.00 |
| Food and Beverage | $1,784.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8,978.57 | 2023-2024 | Spravato |
| Gilead Sciences, INC. | $1,253.98 | 2021-2024 | Epclusa |
| Abbvie INC. | $576.42 | 2021-2024 | |
| Organon LLC | $154.36 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.27 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $120.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biogen, INC. | $117.65 | 2024 | Zurzuvae |
| Otsuka America Pharmaceutical, INC. | $116.94 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $108.48 | 2023 | |
| Pfizer INC. | $92.90 | 2022-2025 | |
| Sanofi Pasteur INC. | $89.68 | 2021 | |
| Insulet Corporation | $89.48 | 2025 | Omnipod |
| Neurocrine Biosciences, INC. | $73.07 | 2023-2025 | Ingrezza |
| Lilly USA, LLC | $62.88 | 2023-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $62.28 | 2024 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $58.86 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Viatris Specialty LLC | $53.08 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $41.55 | 2024-2025 | Inspire |
| Novo Nordisk INC | $30.25 | 2023-2024 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $21.32 | 2025 | Uzedy |
| Ultragenyx Pharmaceutical INC. | $19.78 | 2023 | |
| Glaxosmithkline, LLC. | $15.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vernon Osborn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.